SEC Form 4 · accession 0001123292-16-001673
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Paul Baker
Officer — SVP, Development Sciences
Period of report
Feb 1, 2016
Accepted (ET)
Feb 3, 2016 · 8:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2016 | A | 75,000 | $0.00 | A | 75,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $35.53 | Feb 1, 2016 | A | 75,000 | A | — | Jan 31, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: 50% of the restricted stock vests on February 1, 2018 with the remainder vesting on February 1, 2019, provided the reporting person remains employed by Five Prime Therapeutics, Inc. ("the Company") through each such date.
- F2One-fourth (1/4th) of the shares underlying the option will vest on February 1, 2017, and the remainder of the shares underlying the option vest at a rate of one forty-eighth (1/48th) per month thereafter, provided the reporting person remains employed by the Company through each such date.